Last reviewed · How we verify
FLU-QIV
FLU-QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus.
FLU-QIV is a quadrivalent inactivated influenza vaccine that stimulates immune responses against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | FLU-QIV |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) virus particles or viral antigens from two influenza A strains and two influenza B strains. Upon administration, it triggers both humoral (antibody) and cellular immune responses, enabling the body to recognize and neutralize circulating influenza viruses before they establish infection. This provides seasonal protection against the included viral strains.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fever
- Fatigue
Key clinical trials
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults (PHASE2)
- Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma (PHASE1)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |